Medipost Reaches Agreement with U.S. FDA for Single Phase 3 Trial of Cartistem
Patient Enrollment Reduced from 600 to 300, Clinical Trial Costs Cut by Up to 30%
Phase 3 Trial Completed in Japan, Approval Application Planned for Second Half of the Year
On June 4, Medipost announced that it had reached a final agreement with the U.S. Food and Drug Administration (FDA) to conduct the U.S. Phase 3 clinical trial of Cartistem, a treatment for knee osteoarthritis, as a single pivotal study.
Typically, more than two independent Phase 3 clinical trials are required to obtain new drug approval in the United States. However, Medipost explained that it was granted approval for a single clinical trial design based on domestic clinical results, long-term follow-up data, and real-world evidence (RWE).
According to the company, as a result of this agreement, the size of the U.S. Phase 3 clinical trial has been reduced from the original 600 patients to 300 patients. The clinical trial period is also expected to be shortened by approximately 3 to 6 months compared to previous estimates.
The company also expects clinical trial costs to decrease by about 20 to 30 percent compared to the original plan. However, the number of clinical trial sites will remain at 70 to accelerate patient enrollment. Cartistem, an osteoarthritis treatment using umbilical cord blood-derived mesenchymal stem cells, is already approved and sold in Korea.
Medipost has also completed a Phase 3 clinical trial for Cartistem in Japan and plans to apply for product approval in the second half of this year. The company aims to obtain approval in Japan by 2027.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seungjin Lee, Head of Global Business at Medipost, said, "This is the result of the FDA recognizing the reliability of our clinical data and our clinical trial design," adding, "We will proceed with the U.S. clinical trial and global business development without delay."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.